Enzolytics Inc - ENZC stock
OTC Symbol: ENZC | OTC Tier: Pink Current
Enzolytics Inc (OTC: ENZC) is a biotechnology company focused on developing innovative therapies for infectious diseases, including HIV/AIDS. The company was founded in 2014 and is headquartered in Houston, Texas.
Enzolytics is focused on the development of a proprietary therapeutic protein called ITV-1, which has shown potential as a treatment for a variety of infectious diseases. ITV-1 is a recombinant protein derived from a natural human protein called CD4. The protein has been shown to bind to and inactivate viruses, including HIV, and may also stimulate the immune system's response to these viruses.
Enzolytics is currently conducting preclinical studies and clinical trials to evaluate the safety and efficacy of ITV-1 as a treatment for HIV/AIDS. The company is also exploring the potential use of ITV-1 for other infectious diseases, including COVID-19.
In addition to its work on ITV-1, Enzolytics is also developing a diagnostic test for COVID-19 based on the detection of viral antigens. The company is collaborating with other companies and academic institutions to further advance its product pipeline and expand its operations.
Overall, Enzolytics is focused on developing innovative therapies that have the potential to address significant unmet medical needs. The company is still in the early stages of development and its products are not yet commercially available, but it has demonstrated promising results in preclinical studies and clinical trials, and has generated significant interest from investors and the biomedical community.
